🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

If you're wondering why your boss suddenly started talking about prompt engineering in meetings, you're witnessing the rise of AI literacy as a non-negotiable leadership skill. trib.al/2avYj6Y

🚨Our RWE #perioperative #NSCLC study now in JAMA Network Open study of 1334 pts with stage II–IIIA resectable NSCLC: ◼️Neoadj DMFS @ 18 mo: 80% ◼️Adj DMFS @ 18 mo: 83 % ◼️Uptake was low: <30% ◼️Favorable outcomes, but time to expand access OncoAlert bit.ly/3I5Aeck

👨‍⚕️👩‍⚕️ Damos la bienvenida al nuevo grupo de Médicos (as) Internos (as) de Pregrado del INCan, generación julio 2025 – junio 2026. ¡Éxito en esta etapa de formación profesional! #MIPs #INCan #FormaciónMédica

First positive phase 3 trial for a bispecific ADC (EGFR/HER3 topo1 ADC), co-developed by BiokinPharma & BMS. Bispecific ADCs are coming! fiercebiotech.com/biotech/biokin…

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer with an impact on disease-free survival & overall survival! 🌟 NEJM 2025 nejm.org/doi/full/10.10…

Todavía estás a tiempo de postularte al programa de Apoyo para Congresos Internacionales. ✈️ Recuerda que puedes obtener inscripción, vuelo o apoyo económico. ✅ Modalidades: presentación oral o póster 📅 Vigencia: hasta el 8 de diciembre de 2025

Grateful to have joined the EGFR-mutated NSCLC preceptorship at IEO. Insightful discussions with OncoPolmoneIEO Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Ilaria Attili, MD Carla & the rest of the brilliant faculty. An evolving field where collaboration and continuous learning are key.

Immune Checkpoint Inhibitor‐Based Therapy as the First‐Line Treatment for Advanced NSCLC. Efficacy, challenges & future perspectives, including bispecific antibody targeting PD-1 & VEGF. onlinelibrary.wiley.com/doi/10.1111/17… OncoAlert

Top #BreastCancer Trials for Q2 2025, curated by LARVOL CLIN based on oncologist sentiment on X. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights |

🏨 No te quedes sin Hospedaje para el #congresosmeo2025  Cancún te espera con opciones exclusivas para tu estadía. Reserva ahora 👉 housing.checkmein.com.mx/SMEO2025/esp/ ✅ Tarifas preferenciales ✅ Ubicaciones estratégicas ✅ Gestión a través de agencia oficial

After a phenomenal podcast recording session with Miguel Zugman outlining his experiences at both Einstein Hospital Israelita & City of Hope, was nice to celebrate with a #sushi lunch w Salvador Jaime-Casas, MD & #VitorDeGoesMD!

Limited evidence exists regarding QOL losses experienced by informal cancer caregivers. New #OpenAccess work led by Deakin Health Economics researchers investigates annual opportunity costs, projected informal care costs, and QALE gaps. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert

I will be discussing novel updates in first-line HER2+ Metastatic Breast Cancer! Gathering my thoughts on DB-09 and PATINA now.

Estudiantes y residentes interesados en ser cirujanos oncólogos, así como residentes de cirugía oncológica, ¡no se pierdan esta gran oportunidad! Society of Surgical Oncology Sociedad Mexicana de Oncología, A.C. DocenciaIncan.MX

Dr. Eric J. Small, MD, FASCO "ASCO 2026 highlights the true purpose of translational research: it's not enough to bring discoveries from the lab to the clinic—we must ensure that this knowledge transforms the lives of patients, wherever they live”@JoChien UC San Francisco Instituto Nacional de Cancerología

👏👏👏👏

The FDA granted breakthrough therapy designation to first-line treatment with trastuzumab deruxtecan (Enhertu) plus pertuzumab (Perjeta) for unresectable or metastatic HER2+ #BreastCancer. Check out this CURE Today interview where Dr. Sara Tolaney (Sara Tolaney) discusses the